Contact

info@syndevrx.com

1 Broadway # 14, Cambridge, MA 02142

Decellularized extracellular matrix scaffolds identify full-length collagen VI as a driver of breast cancer cell invasion in obesity and metastasis

We show that decellularized ECM from tumor-bearing and obese mammary glands drives TNBC cell invasion. Proteomics of the ECM from the obese mammary gland led us to identify full-length collagen VI as a novel driver of TNBC cell invasion whose abundance in tumor stroma increases with body mass index in human TNBC patients. Last, we […]

Read More

SynDevRx Clinical Drug Candidate SDX-7320 Offsets Hyperglycemia Caused by PI3K/Akt/mTOR Cancer Therapies and Restores Insulin Sensitivity, Preclinical Studies Show

SynDevRx, Inc., a clinical-stage oncology company, announces the completion of a series of preclinical studies demonstrating that its anti-cancer drug candidate, SDX-7320, inhibits PI3K/Akt inhibitor-induced hyperglycemia and subsequent hyperinsulinemia in normal mice and inhibits tumor growth in multiple models of HR+ breast cancer. The company’s ongoing research places them at the vanguard of metabo-oncology, an emerging field of cancer research that focuses on the role metabolic hormones play in the development and progression of many common cancers, as well as tumor resistance developed in response to certain treatment.

Read More

Metabolic Hormone Leptin Linked to COVID-19

The hormone leptin that connects the body’s metabolism and immune response system may explain why COVID-19 is so dangerous for people with obesity. “The problem for people with obesity is that their leptin levels are always high, and that can affect the response to a COVID-19 infection,” said Candida Rebello, PhD, RD, lead author of […]

Read More

Co-Founder and Chief Business Officer James Shanahan Discusses Metabo-Oncology and Breast Cancer

Read More

AACR 2020: SynDevRx Selected to Present the Results from its Phase 1 Study of SDX-7320 in Late-Stage Cancer Patients

SynDevRx recently completed a Phase 1 study in late-stage cancer patients with a variety of solid tumors. The initial results from the clinical study were selected by AACR for presentation by one of the Principle Investigators – Dr. Monica Mita, MD. Dr. Mita is a Professor of Medicine, Co-Director, Experimental Therapeutics Program at Cedars-Sinai Medical […]

Read More

SynDevRx Dec 2019 San Antonio Poster on Hyperglycemia Inhibition with PI3K

SynDevRx Poster Dec 2019 SABCS Hyperglycemia PI3K

Read More

Insulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer

…insulin signaling can be seen as enabling tumor development by providing a mechanism for PI3K activation and enhanced glucose uptake. This idea is supported by studies showing enhanced tumor development in humans and mice with hyperinsulinemia, and reduced tumor development in states of reduced insulin levels.

Read More

Metabo-Oncology: The Latest Frontier in Cancer Research

There is a new field of cancer research that is only just now starting to take shape but is promising to greatly increase our understanding of cancer and what can influence how it develops over time. This field is being called metabo-oncology.

Read More

SynDevRx launches Metabo-Oncology.com website

Metabo-Oncology press release 26Mar 2019 FINAL

Read More

SDX at AACR: Obesity confers immuno-suppressive tumor microenvironment – Poster Presentation

April 1, 8:00 AM to 12:00 PM 1226 / 4 – A novel polymer-conjugated methionine aminopeptidase 2 (MetAP2) inhibitor SDX-7320 inhibits the growth of EO771 mammary gland tumors and ameliorates the immunosuppressive tumor immune micro-environment (TIME)

Read More